Literature DB >> 10591027

Influence of transgenic overexpression of phospholamban on postextrasystolic potentiation.

B D Hoit1, D A Tramuta, V J Kadambi, R Dash, N Ball, E G Kranias, R A Walsh.   

Abstract

Twelve mice with PLB overexpression (PLBOE), and 11 isogenic FVB/N wild-type (WT) controls, were anesthetized and instrumented with a 1.4 F Millar catheter in the LV and a 1 F pacemaker in the right atrium. At a cycle length of 200 ms and a fixed extrastimulus of 120 ms, extrastimuli with increasing intervals (PESI) up to 1000 ms were introduced, and the peak rates of LV isovolumic contraction (+/- dP/dtmax) were normalized and fit to monoexponential equations. In a subset of animals, the protocols were repeated after ryanodine (4 ng/g) was given to deplete SR Ca2+ stores. The time constant and the plateau of the exponential curve fits were significantly greater in PLBOE than WT (107.8 +/- 7.0 v 75.2 +/- 5.5 ms and 1.39 +/- 0.03 v 1.08 +/- 0.02, both P < 0.05). At 200, 600 and 1000 ms, the normalized dP/dt was significantly greater in PLBOE than WT. After ryanodine, normalized dP/dt was significantly decreased in PLBOE, but unchanged in WT. The protein levels of the sodium-calcium exchanger normalized to calsequestrin were increased 3.7 +/- 0.3-fold in PLBOE compared to controls. In conclusion, the phospholamban level is a critical determinant of postextrasystolic potentiation in this transgenic model, and is differentially impaired by ryanodine at long diastolic intervals in PLBOE v controls. These differences may be due in part to changes in the protein level and resultant activity of the sodium calcium exchanger.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10591027     DOI: 10.1006/jmcc.1999.1031

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  8 in total

Review 1.  Cellular mechanisms of arrhythmogenic cardiac alternans.

Authors:  Kenneth R Laurita; David S Rosenbaum
Journal:  Prog Biophys Mol Biol       Date:  2008-02-15       Impact factor: 3.667

2.  Post-extrasystolic Blood Pressure Potentiation as a Risk Predictor in Cardiac Patients.

Authors:  Alexander Steger; Daniel Sinnecker; Petra Barthel; Alexander Müller; Josef Gebhardt; Georg Schmidt
Journal:  Arrhythm Electrophysiol Rev       Date:  2016-05

3.  Post-extrasystolic Potentiation: Link between Ca(2+) Homeostasis and Heart Failure?

Authors:  David J Sprenkeler; Marc A Vos
Journal:  Arrhythm Electrophysiol Rev       Date:  2016-05

Review 4.  Ca2+ signaling of human pluripotent stem cells-derived cardiomyocytes as compared to adult mammalian cardiomyocytes.

Authors:  Xiao-Hua Zhang; Martin Morad
Journal:  Cell Calcium       Date:  2020-06-13       Impact factor: 6.817

Review 5.  Mechanisms and potential therapeutic targets for ventricular arrhythmias associated with impaired cardiac calcium cycling.

Authors:  Kenneth R Laurita; David S Rosenbaum
Journal:  J Mol Cell Cardiol       Date:  2007-10-25       Impact factor: 5.000

6.  An Augmented Negative Force-Frequency Relationship and Slowed Mechanical Restitution Are Associated With Increased Susceptibility to Drug-Induced Torsade de Pointes Arrhythmias in the Chronic Atrioventricular Block Dog.

Authors:  David J Sprenkeler; Alexandre Bossu; Jet D M Beekman; Marieke Schoenmakers; Marc A Vos
Journal:  Front Physiol       Date:  2018-08-08       Impact factor: 4.566

7.  Aortic acceleration as a noninvasive index of left ventricular contractility in the mouse.

Authors:  Jorge Enrique Tovar Perez; Jesus Ortiz-Urbina; Celia Pena Heredia; Thuy T Pham; Sridhar Madala; Craig J Hartley; Mark L Entman; George E Taffet; Anilkumar K Reddy
Journal:  Sci Rep       Date:  2021-01-12       Impact factor: 4.379

8.  Postextrasystolic blood pressure potentiation predicts poor outcome of cardiac patients.

Authors:  Daniel Sinnecker; Ralf J Dirschinger; Petra Barthel; Alexander Müller; Adrian Morley-Davies; Alexander Hapfelmeier; Michael Dommasch; Katharina M Huster; Gerd Hasenfuss; Karl-Ludwig Laugwitz; Marek Malik; Georg Schmidt
Journal:  J Am Heart Assoc       Date:  2014-06-03       Impact factor: 5.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.